Дисфункция β-клеток при сахарном диабете 2 типа: возможности современной сахароснижающей терапии


DOI: https://dx.doi.org/10.18565/pharmateca.2021.12.60-65

Н.А. Черникова

Кафедра эндокринологии, Российская медицинская академия непрерывного профессионального образования, Москва, Россия
В настоящем обзоре раскрываются современные представления о роли дисфункции β-клеток в возникновении и развитии сахарного диабета 2 типа (СД2). Описаны патологические процессы, которые лежат в основе нарушения секреции инсулина при СД2. Приводятся данные о влиянии современной сахароснижающей терапии на функциональное состояние β-клеток.

Литература


1. Ludvik B., Nolan J.J., Baloga J., Sacks D., Olefsky J. Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes. 1995;44:1121–25. Doi: 10.2337/diab.44.9.1121.


2. Polonsky K.S. Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord. 2000;24(Suppl. 2):S29–S31. Doi: 10.1038/sj.ijo.0801273.


3. Ferrannini E., Natali A., Bell P., et al. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100(5):1166–73. Doi: 10.1172/JCI119628.


4. Tabak A.G., Jokela M., Akbaraly T.N., et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215–21. Doi: 10.1016/S0140-6736(09)60619-X.


5. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16–21. Doi: 10.2337/diabetes.53.suppl_3.s16.


6. Brown R.J., Rother K.I. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes. 2008;9(3 Pt 2):14–22. Doi: 10.1111/j.1399-5448.2007.00272.


7. Ferrannini E. The stunned beta cell: a brief history. Cell Metab. 2010;11(5):349–52. Doi: 10.1016/j.cmet.2010.04.009.


8. Butler A.E., Janso J., Bonner-Weir S., et al Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–10. Doi: 10.2337/diabetes.52.1.102.


9. Rahier J., Guiot Y., Goebbels R.M., et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(Suppl. S4):32–42. Doi: 10.1111/j.1463-1326.2008.00969.x.


10. Halban P.A., Polonsky K.S., Bowden D.W., et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab. 2014;99(6):1983–92. Doi: 10.1210/jc.2014-1425.


11. Eizirik D.L., Cardozo A.K., Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocrinol Rev. 2008;29:42–61. Doi: 10.1210/er.2007-0015


12. Laybutt D.R., Preston A.M., Akerfeldt M.C., et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia. 2007;50:752–63. Doi: 10.1007/s00125-006-0590-z


13. Tiedge M., Lortz S., Drinkgern J., Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes. 1997;46:1733–42. Doi: 10.2337/diab.46.11.1733.


14. Kruit J.K., Wijesekara N., Fox J.E., et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes. 2011;60:3186–96. Doi: 10.2337/db11-0081.


15. Del Guerra S, Lupi R, Marselli L, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes. 2005;54:727–35. Doi: 10.2337/diabetes.54.3.727.


16. Masters S.L., Dunne A., Subramanian S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol. 2010;11:897–904. Doi: 10.1038/ni.1935.


17. Richardson S.J., Willcox A., Bone A.J., Foulis A.K., Morgan N.G. Islet-associated macrophages in type 2 diabetes. Diabetologia. 2009;52:1686–88. Doi: 10.1007/s00125-009-1410-z


18. Boni-Schnetzler M., Thorne J., Parnaud G., et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008;93:4065–74. Doi: 10.1210/jc.2008-0396.


19. Larsen C.M., Faulenbach M., Vaag A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–26. Doi: 10.1056/NEJMoa065213.


20. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003;52:581. Doi: 10.2337/diabetes.52.3.581.


21. Tabák A.G., Jokela M., Akbaraly T.N., et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215–21. Doi: 10.1016/S0140-6736(09)60619-X.


22. Russo G.T., Giorda C.B., Cercone S., et al. Beta cell stress in a 4-year follow-up of patients with type 2 diabetes: a longitudinal analysis of the BetaDecline Study. Diabetes Metab Res Rev. 2018;34(6):e3016. Doi: 10.1002/dmrr.3016.


23. Hou X., Liu J., Song J., et al. Relationship of Hemoglobin A1c with β Cell Function and Insulin Resistance in Newly Diagnosed and Drug Naïve Type 2 Diabetes Patients. J Diabetes Res. 2016;2016:8797316. Doi: 10.1155/2016/8797316.


24. Gleason C.E., Gonzalez M., Harmon J.S., Robertson R.P. Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab. 2000;279:E997–1002. Doi: 10.1152/ajpendo.2000.279.5.E997.


25. Poitout V., Amyot J., Semache M., et al. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta. 2010;1801:289–98. Doi: 10.1016/j.bbalip.2009.08.006.


26. Cunha D.A., Hekerman., Cardozo A.K., Bellomo, E., et al. Initiation and execution of lipotoxic ER stress in pancreatic beta-cells. J Cell Sci. 2008;121:2308–18. Doi: 10.1242/jcs.026062.


27. Weng J., Li Y., Xu W., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet 2008;371:1753–60. Doi: 10.1016/S0140-6736(08)60762-X.


28. Ashcroft F.M., Gribble F.M. ATP-sensitivi K+channels and insulin secretion: their role in health and disease. Diabetologia. 1999;2(8):903–19. Doi: 10.1007/s001250051247.


29. Bunck M.C., Diamant M., Corner A., et al. One- year treatment with exenatide improves betacell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762–68. Doi: 10.2337/dc08-1797.


30. Gerstein H.C., Bosch J., Dagenais G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28. Doi: 10.1056/NEJMoa1203858.


31. Mcinnes N., Hall S., et al. 677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial. Diabetes. 2021;70(Supplement 1):677-P. Doi:10.2337/db21-677-P.


32. Xu W., Li Y.B., Deng W.P., Hao Y.T., Weng J.P. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chinese Med Jю 2009;122:2554–59.


33. Retnakaran R., Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function. Diabetes Obes Metab 2012;14(Suppl 3):161–66. Doi: 10.1111/j.1463-1326.2012.01658.x.


34. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43. Doi: 10.1056/NEJMoa066224.


35. Patane G., Piro S., Rabuazzo A.M., et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000;49:735–40. Doi: 0.2337/diabetes.49.5.735.


36. Simon-Szabo L., Kokas M., Mandl J., et al. Metformin attenuates palmitate induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. PLoS One. 2014;9:e97868. Doi: 10.1371/journal.pone.0097868.


37. DeFronzo R.A., Tripathy D., Schwenke D.C., et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15. Doi: 10.1056/NEJMoa1010949.


38. Lupi R., Del Guerra S., Marselli L., et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab. 2004;286:E560–67. Doi: 10.1152/ajpendo.00561.2002.


39. Russo G.T., Giorda C.B., Cercone S., et al. Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study. PLoS One. 2014;9(10):e109702. Doi: 10.1371/journal.pone.0109702.


40. Maedler K., Carr R.D., Bosco D., et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501–6. Doi: 10.1210/jc.2004-0699.


41. UK Prospective Diabetes Study 16: Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–58. Doi: 10.2337/diab.44.11.1249.


42. Kahn S.E., Lachin J.M., Zinman B., et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60:1552–60. Doi: 10.2337/db10-1392.


43. Drucker D.J., Philippe J., Mojsov S., et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA. 1987;84:3434–38. Doi: 10.1073/pnas.84.10.3434.


44. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–76. Doi: 10.2337/diabetes.48.12.2270.


45. Farilla L., Bulotta A., Hirshberg B., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149–58. Doi: 10.1210/en.2003-0323.


46. Derosa G., Carbone A., D’Angelo A., et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Expert Opin Pharmacother. 2012;13:2433–42. Doi: 10.1517/14656566.2012.730519.


47. Ohkura T., Fujioka Y., Sumi K., et al. Sitagliptin improves the impaired acute insulin response during a meal tolerance test in Japanese patients with type 2 diabetes mellitus: a small-scale real-world study. Diabetes Ther. 2014;5:285–97. Doi: 10.1007/s13300-014-0071-1.


48. Cunha D.A., Ladriere L, Ortis F., et al. Glucagon like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes. 2009;58:2851–62. doi: 10.2337/db09-0685.


49. Natalicchio A., Labarbuta R., Tortosa F., et al. Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. Diabetologia. 2013;56:2456–66. Doi: 10.1007/s00125-013-3028-4.


50. Shimo N., Matsuoka T.A., Miyatsuka T., et al. Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key beta-cell factors under diabetic conditions. Biochem Biophys Res Commun. 2015;467:948–54. Doi: 10.1016/j.bbrc.2015.10.038.


51. Okauchi S., Shimoda M., Obata A., et al. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db/db mice. Biochem Biophys Res Commun. 2016;470:772–82. Doi: 10.1016/j.bbrc.2015.10.109.


52. Rosenstock J., Aggarwal N., Polidori D., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–38. Doi: 10.2337/dc11-1926.


53. Matthews D.R., Paldánius P.M., Proot P., et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394:1519–29. Doi: 10.1016/S0140-6736(19)32131-2.


54. Meier J.J., Schenker N., Kahle M., et al. Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study. Diabetes Obes Metab. 2017;19(11):1625–29. Doi: 10.1111/dom.12968.


Об авторах / Для корреспонденции


Автор для связи: Наталья Альбертовна Черникова, к.м.н., доцент кафедры эндокринологии, Российская медицинская академия непрерывного профессионального образования, Москва, Россия; ORCID: https://orcid.org/0000-0002-0562-8396


Похожие статьи


Бионика Медиа